Amy D. Tiersten, MD

Healio spoke with Amy Tiersten, MD, professor of medicine with Mount Sinai Hospital, about the treatment landscape in HER2-positive breast cancer.

A liquid biopsy-based approach to treatment selection improved outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

The addition of pembrolizumab to first-line chemotherapy led to statistically significant improvement in PFS and OS among patients with PD-L1-positive metastatic triple-negative breast cancer, according to results of the KEYNOTE-355 trial.

One year of adjuvant olaparib significantly extended invasive and distant DFS among patients with high-risk, HER2-negative early-stage breast cancer and germline BRCA1/BRCA2 mutations, according to results of the phase 3 OlympiA study.

Breast cancer survivors of childbearing age appeared considerably less likely than women in the general population to become pregnant, according to study results presented at the virtual San Antonio Breast Cancer Symposium.

Tucatinib plus trastuzumab and capecitabine extended OS among patients with brain metastases from HER2-positive breast cancer, according to findings from a randomized phase 3 study presented during the ASCO20 Virtual Scientific Program and simultaneously published in Journal of Clinical Oncology.

A year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer, according to study results presented at ASCO20 Virtual Scientific Program.

The addition of pembrolizumab to various chemotherapy partners improved PFS among certain patients with inoperable or metastatic triple-negative breast cancer, according to study results presented at ASCO20 Virtual Scientific Program.

SAN ANTONIO — A novel combination of oral paclitaxel plus encequidar significantly improved overall response rates compared with IV paclitaxel among women with metastatic breast cancer, according to results of a randomized phase 3 study presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Adjuvant ado-trastuzumab emtansine reduced risk for invasive recurrence by 50% compared with trastuzumab among patients with HER2-positive early breast cancer who still had residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy, according to results of the KATHERINE trial presented at San Antonio Breast Cancer Symposium.